Inflation Hits Cannabis Industry as Prices Rise

Aug.09.2022
Inflation Hits Cannabis Industry as Prices Rise
Inflation is impacting the cannabis industry, with one in four retailers reporting plans to raise prices by over 10%.

Although inflation has already disrupted many people's plans for summer off-road trips, the impact of rising prices could soon cause real harm to certain individuals.


So far, marijuana and many related products have largely shed the double-digit growth seen in many foods, from chicken to avocados. An analysis firm even reported that prices for marijuana flowers, edibles, and vape products fell by 16.7%, 11.8%, and 12.4%, respectively, between January 2021 and 2022.


Due to a variety of interconnected reasons, such as lack of available materials and supply chain disruptions, the prices of most things have been steadily and rapidly increasing at a rate unseen in 40 years. Even if the prices of main products have not risen, the increase in packaging material costs has had little effect on any industry.


From June 2021 to June 2022, the Consumer Price Index has increased 9.1%. Additionally, according to a recent report from the cannabis industry and accounting firm GreenGrowth CPAs, the cannabis industry may finally be experiencing inflation. With labor and material costs for producing ready-to-eat cannabis products on the rise, one in four cannabis retailers report that they have already increased or plan to increase prices by 10% or more next year.


According to the report, the impact of the COVID-19 pandemic on cannabis businesses has been relatively limited. Based on last year's data, supply chain and recruitment difficulties were reported as issues affecting almost all industries in 2021, in addition to supply challenges being the most common issue currently impacting operators. The survey examined over 700 companies in states where recreational or medical cannabis use is legal, including startups and large multinational operators. While 70% of operators reported they would attempt to absorb rising costs rather than raise prices, 30% plan to proactively increase prices to prevent losses.


The survey found that there were differing opinions among respondents regarding responsibility for rising inflation, with 40% citing policies of the Biden administration and 30% attributing it to lingering impacts of the Trump administration. Other reasons quoted by operators included supply-chain issues, conflicts with countries like Russia and China, and effects of the oil industry's operations. Nationwide numbers are not entirely reflective as marijuana use and production currently remain illegal at a federal level. However, despite price increases, demand for marijuana has remained strong during and after the COVID-19 outbreak. Since the start of quarantine, some online delivery services in California have seen sales increase by 500%.


After two years of crisis and uncertainty following the global pandemic, cannabis financial operators find themselves navigating a range of new, complex situations and business obstacles," the report states. "But it's not all bad news. Many operators have benefited from the surge in demand and are using this new windfall to develop ambitious growth plans.


Statement


This article is compiled from third-party information and is intended for industry communication and learning purposes only.


This article does not represent the views of 2FIRSTS and 2FIRSTS cannot confirm the authenticity or accuracy of the article's content. The translation of this article is only intended for industry communication and research.


Due to limitations in translation proficiency, the translated article may not fully correspond with the original text. Therefore, the original text should be referred to for accuracy.


2FIRSTS maintains complete alignment with the Chinese government on all domestic, Hong Kong, Macau, Taiwan, and foreign affairs positions and statements.


The copyright of the compiled information belongs to the original media and author, and if there is any infringement, please contact us for removal.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

Small ENDS Manufacturers Press FDA on Abuse Liability Standards as Agency Defines Pharmacological Review Framework
Small ENDS Manufacturers Press FDA on Abuse Liability Standards as Agency Defines Pharmacological Review Framework
At the third session of its PMTA roundtable, the FDA outlined its framework for assessing abuse liability in ENDS products, emphasizing the role of nicotine pharmacokinetics and product-specific data in APPH determinations. Small manufacturers questioned the high cost of clinical PK studies and the absence of defined numeric thresholds, while raising bridging strategies and PBPK modeling as potential alternatives.
Feb.11
Research Summary | NHANES Study: Smoking or E-Cigarette Use Linked to Higher Prevalence of Elevated Blood Pressure and Hypertension
Research Summary | NHANES Study: Smoking or E-Cigarette Use Linked to Higher Prevalence of Elevated Blood Pressure and Hypertension
A cross-sectional analysis based on the US NHANES 2021–2023 cycle, including 6,262 participants aged over 12, found that compared with people who neither smoke nor vape, those who smoke and/or use e-cigarettes had a higher prevalence of elevated blood pressure and hypertension. After full adjustment, smoking/vaping was associated with elevated blood pressure (aOR 1.34) and hypertension (aOR 1.46), and with a 1.05 mmHg higher diastolic blood pressure.
Feb.09 by 2FIRSTS.ai
Product | Clear Tank, Airflow Control and Three-Dimension Flavor Labels: RELX Launches Disposable DIVA in South Korea
Product | Clear Tank, Airflow Control and Three-Dimension Flavor Labels: RELX Launches Disposable DIVA in South Korea
RELX has recently launched its disposable e-cigarette, the RELX DIVA, on online channels in South Korea, offering two nicotine strengths of 0.98% and 1.98%. Publicly available information shows the device features a 20 mL e-liquid capacity and is rated for around 30,000 puffs, alongside a 750 mAh rechargeable battery and two power modes—BOOST and ECO—at approximately 16W and 13W, respectively.
Feb.05 by 2FIRSTS.ai
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
U.S.-based medical startup Qnovia Inc. reported positive results from its first-in-human clinical trial of RespiRx, an inhalable nicotine replacement therapy (NRT) device designed to support smoking cessation.
Innovation
Feb.24
Nicotine Becomes Second-Largest Revenue Source for Couche-Tard in Fiscal 2025
Nicotine Becomes Second-Largest Revenue Source for Couche-Tard in Fiscal 2025
Alimentation Couche-Tard reported that nicotine products accounted for 9% of total revenue in fiscal 2025, making it the company’s second-largest revenue source after fuel, according to its latest Business Strategy Update.
Market
Feb.19
U.S. FDA Posts Final ZYN MRTP Materials, Sets March 4 Deadline for Public Comments
U.S. FDA Posts Final ZYN MRTP Materials, Sets March 4 Deadline for Public Comments
U.S. FDA has released the final batch of materials for ZYN MRTP applications and set March 4 (11:59 p.m. ET) as the deadline for public comments to be considered in the agency’s review.
Feb.03 by 2FIRSTS.ai